peptide-evidence

The Peptide Bait and Switch: A Classic Scam and What You Can Do About It

By Published Last reviewed 5 min read

In brief

Here's another peptide scam to watch for: 14 published report records identified tirzepatide where retatrutide was expected. This advisory explains what to check before trusting a label or an apparent effect, using selected reports that cannot establish how common the scam is or who caused each mismatch.

14 report records · 8 vendor names · source-linked audit

You paid for retatrutide. You feel less hungry. The scale moves. None of that proves the label is telling the truth.

Tirzepatide and semaglutide also affect appetite and body weight. A substitution could therefore produce convincing results. Knowingly selling one as another is a bait and switch; a lab mismatch alone does not prove intent or identify who caused it.

What the retatrutide lab reports found

We found 14 published report records identifying tirzepatide where retatrutide was expected, across eight vendor names. Some concern the same batch, so they are not 14 separate incidents or a measure of how common the scam is. Below is one of those records, followed by a separate wrong-substance finding.

99.269% pure. The wrong peptide.Peptide Sciences · April 22, 2025
Finnrick public result page: Peptide Sciences sample expected to contain retatrutide 6mg, but reporting tirzepatide 4.38mg at 99.269% purity; batch RET7920231109-6.
Expected: retatrutide 6mg. Reported: tirzepatide 4.38mg. Purity describes the detected compound. This is a crop of Finnrick's public result page, not the original certificate. Source result · TitrateLab record · Full screenshot.
No peptide detected.Chromate #38002 · August 4, 2026
Original Chromate certificate 38002 for AgeREcode: product Retatrutide 60mg, batch H-061927, identity result 4-Hydroxyacetophenone, remark No peptide detected.
A separate case, outside the 14. This original certificate lists AgeREcode's product as retatrutide 60mg and identifies 4-hydroxyacetophenone. It does not report another GLP-1 peptide. Verify certificate · TitrateLab record · Enlarge original.

A cheaper molecule can still have an effect

Our saved October 3 price snapshot shows a price gap worth examining:

Vertical columns starting at zero: retatrutide $12.50 per labelled 10mg vial; tirzepatide $8.83, 29% less; semaglutide $8.00, 36% less. Mean prices normalized from ten-vial packs, from three, three and one tracked offers respectively.
Tirzepatide: 29% less. Semaglutide: 36% less. Ten-vial pack prices, divided by ten. Enlarge chart.

These are ten-vial packages normalized per vial, including TitrateLab’s retail margin and excluding shipping. The means use three, three and one supplier observations respectively, mixing US-stock and international delivery. Equal milligrams do not mean equivalent doses. This is a saved retail-price comparison, not proof of a seller’s costs or motive.

See live retatrutide prices, tirzepatide prices and semaglutide prices. Those pages update; the chart uses the saved snapshot linked below.

For price differences between sellers, see our retatrutide kit and single-vial price comparison.

The consequences go beyond the price

In a separate September 14 alert, Australia’s TGA described a product sold as retatrutide that contained semaglutide and no retatrutide. Its investigation followed a report of uncontrollable vomiting, a torn oesophagus and hospitalization. That case is outside our 14-report count. Read the regulator’s findings.

Past results cannot authenticate the next vial, either. If its contents change, the previous experience does not establish the new compound or amount.

Lessons learned

  1. An effect cannot identify a compound. Appetite suppression or weight loss cannot authenticate retatrutide. Ask the lab whether its identity methods can distinguish it from tirzepatide and semaglutide.

  2. Read identity and measured amount before the purity headline. The Peptide Sciences example reported 99.269% purity for the wrong peptide. A high percentage alone cannot establish that the vial contains the labelled compound or amount.

  3. Connect the report to the stock you bought. Verify the original record with the laboratory and check the compound, batch code, strength and dates. Independently submitting a sample from purchased stock gives evidence beyond a seller’s selected certificate.

Start with our COA verification guide. If arranging a test, the peptide testing-lab comparison covers prices, methods and sample requirements so you can ask for the checks that answer your question.

A report still describes the submitted sample. It does not certify every vial, exclude every contaminant or establish safety for human use.

Inspect all 14 records and the method

Reviewed October 3, 2026. Thirteen Finnrick source records and one XTP Janoshik report explicitly name tirzepatide where retatrutide was expected. Report dates run February 14, 2025 to July 23, 2026. These are report records, including repeat testing of some batch codes, not unique vials, batches or a prevalence estimate. Identity failures without a named replacement, unresolved extractions and mixtures were excluded. The Chromate and TGA cases above are separate.

For the evidence and vendor response behind one of these records, read the XTP retatrutide substitution investigation.

Download the 14-record source ledger (CSV)

Vendor nameTest datePrinted batchSource record
Alimo Peptide2025-08-04Not recordedKrause Analytical report record
Elite Research USA2026-05-08RT202026BBBTLabs report record
Forever Young Pharmacy2025-02-19224992MZ Biolabs report record
Forever Young Pharmacy2025-02-14224992Chromate report record
Modern Aminos2025-07-09Not recordedChromate report record
Peptide Sciences2025-05-07RET7920231109-6Krause Analytical report record
Peptide Sciences2025-04-25RET7920231109-6Freedom Diagnostics report record
Peptide Sciences2025-04-22RET7920231109-6Janoshik report record
Peptide Sciences2025-04-22RET7920231109-6Janoshik report record
Peptide Sciences2025-02-19RET7920231124-6MZ Biolabs report record
Peptide Sciences2025-02-14RET7920231124-6Chromate report record
Steady Meds2026-03-13Not recordedBTLabs report record
Super Peptides2026-03-13January 8, 2026BTLabs report record
XTP2026-07-23XTP-R30-003Janoshik report record

The historical tests and saved October 3 asking prices concern different observations. Price differences are calculated as (retatrutide mean minus alternative mean) divided by retatrutide mean. Snapshot CSVs: retatrutide, tirzepatide, semaglutide. TitrateLab facilitates orders; these retail prices include its margin.

Compiled by TitrateLab Research Desk with AI-assisted searching, extraction and drafting. Screenshots preserve source wording; the Finnrick original certificate currently requires membership. Methods and correction contact.

Vendor and manufacturer names are used descriptively to identify parties in the documentary record; inclusion is not endorsement. Think a passage misrepresents the record? [email protected].